Acknowledgments
Lestaurtinib was supplied to the MPD-RC for this trial by Teva pharmaceuticals.
Potential conflict of interest
Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2018.1532509.